INTEGRA LIFESCIENCES HOLDINGS CORP (IART) Form 10-Q — Oct 23, 2026
Integra LifeSciences reported Q3 2026 revenue of $411.2 million, up 2.3% year over year, and swung to net income of $14.9 million ($0.19 per diluted share) from a prior-year loss of $5.4 million that included a $511.4 million goodwill impairment. The quarter was weighed down by July flash flooding at the company's Cincinnati facility, which caused roughly $22.2 million in restoration costs and an estimated $7 million revenue hit; Integra received a $10 million initial insurance payment and booked an $11.4 million receivable, with full manufacturing capacity expected in Q2 2027.
Key figures
- Eps
- 0.19
- Revenue
- 411182000
- Net Income
- 14852000
- Total Debt
- 1826588000
- Revenue Yoy
- Q3 2026 vs Q3 2025: +2.3% ($411.2M vs $402.1M)
- Total Assets
- 3507798000
- Cash Position
- 252261000
- Shares Outstanding
- 77800976
- New 2033 notes
- $450.0M at 9.5% due Nov 1, 2033
- Greer acquisition
- $15.0M cash, completed October 5, 2026
- Q3 revenue growth
- +2.3%
- Insurance received
- $10.0M initial payment plus $11.4M receivable
- Nine month revenue
- 1221861000
- Dourepair payment due
- $20.0M in October 2026
- Cincinnati flood costs
- 22200000
- October 2026 refinancing
- Term Loan A $600M due 2031, Term Loan B $450M due 2033, revolver $600M due 2031
- Cincinnati revenue impact
- ~$7M lost in Q3 2026
- Securitization outstanding
- 81200000
- Goodwill headroom neurosurgery
- 15.3%
- Prior year goodwill impairment
- 511365000
- Senior credit facility outstanding
- $1,747.5M ($697.5M term loan + $1,050.0M revolver)
- Goodwill headroom tissue reconstruction
- 11.3%
- Weighted avg interest rate senior credit
- 5.6%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.